Halozyme Therapeutics (GB:0J2O)

Halozyme (0J2O) Share Price & Analysis


0J2O Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$30.09 - $58.68
Previous Close$38.25
Average Volume (3M)286.00
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$348.27M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)N/A
Nov 07, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding131,920,880
10 Day Avg. Volume104
30 Day Avg. Volume286
Standard Deviation0.09
Financial Highlights & Ratios
Price to Book (P/B)-6.53
Price to Sales (P/S)28.54
Price to Cash Flow (P/CF)19.00
P/FCF Ratio18.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside47.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8




What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest share price was $30.09 and its highest was $58.67 in the past 12 months.
    What is Halozyme Therapeutics’s market cap?
    Currently, no data Available
    When is Halozyme Therapeutics’s upcoming earnings report date?
    Halozyme Therapeutics’s upcoming earnings report date is Nov 07, 2023 which is in 38 days.
      How were Halozyme Therapeutics’s earnings last quarter?
      Halozyme Therapeutics released its earnings results on Aug 08, 2023. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.11.
        Is Halozyme Therapeutics overvalued?
        According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Halozyme Therapeutics pay dividends?
          Halozyme Therapeutics does not currently pay dividends.
          What is Halozyme Therapeutics’s EPS estimate?
          Halozyme Therapeutics’s EPS estimate is $0.75.
            How many shares outstanding does Halozyme Therapeutics have?
            Currently, no data Available
            What happened to Halozyme Therapeutics’s price movement after its last earnings report?
            Halozyme Therapeutics reported an EPS of $0.74 in its last earnings report, beating expectations of $0.63. Following the earnings report the stock price went up 4.517%.
              Which hedge fund is a major shareholder of Halozyme Therapeutics?
              Among the largest hedge funds holding Halozyme Therapeutics’s share is Driehaus Capital Management LLC. It holds Halozyme Therapeutics’s shares valued at 19M.


                Halozyme Stock Smart Score

                The Halozyme Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Halozyme Therapeutics

                Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Sarepta Therapeutics
                Fate Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis